Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.

By Michael P. Curry, J. O’Leary, N. Bzowej, A. Muir, K. Korenblat, J. Fenkel, K. Reddy, E. Lawitz, S. Flamm, T. Schiano and 12 more. New England Journal of Medicine, 2015

800 citations recorded by the source corpus.

Subfields: Emergency Medicine, Hepatology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/51616c669b0406b1151460f4e70b6af953369568

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. Christoph Sarrazin
2. A. Aghemo
3. G. Dusheiko
4. M. Puoti
5. X. Forns
6. J. Pawlotsky

Citations in the corpus

• EASL Recommendations on Treatment of Hepatitis C 2018. (2018, methodology): “Of the patients who had a baseline MELD score ≥15, 81% (22/27) had an improved MELD score, 11% (3/27) had no change in their MELD score, and 7% (2/27) had a worse MELD score.(120) In these studies, the median MELD score improvement was 2 points (range: 1–17), not always followed by clinical improvem”
• EASL recommendations on treatment of hepatitis C - Final update of the series. (2020, background): “mised to receive the fixed-dose combination of sofosbuvir and velpatasvir for 12 weeks without ribavirin, for 12 weeks with weight-based dosed ribavirin, or for 24 weeks without ribavirin.(173) The SVR12 rates with these 3 treatment regimens,”
• Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. (2015, neutral): “Headache 24 (18) 29 (22) 90 (32) 89 (32)”